Our Leadership

U.S. Executive Leadership Team

Christopher Posner, President and CEO, LEO Pharma Inc. 

Christopher Posner is LEO Pharma’s Executive Vice President of Region U.S. and President and CEO of LEO Pharma Inc., the U.S. affiliate. Chris joined LEO Pharma from R-Pharm U.S., a specialty pharmaceutical start-up focused on oncology and chronic immune diseases, where he was Head of Worldwide Commercial Operations. Chris has extensive experience in the healthcare industry including biologic medicines as well as immunology, and he led the commercialization of national and global brands at Bristol-Myers Squibb, Pfizer, Wyeth, Endo Pharmaceuticals and Merck. Before joining the pharmaceutical industry, Chris was a senior economic consultant at Wharton Econometric Forecasting Associates. Chris earned his MBA from Fuqua School of Business, Duke University, and his Bachelor of Arts degree in economics from Villanova University.

Keith Bernius, CFO and VP, Business Operations 

Keith Bernius is LEO Pharma Inc.’s Chief Financial Officer and Vice President of Business Operations. Prior to joining LEO Pharma, Keith was the Vice President of Finance and Treasurer of Altegrity Inc., where he was responsible for global treasury, investor relations, risk management, enterprise FP&A and real estate. Prior to Altegrity, he worked at Alpharma Pharmaceuticals for seven years in both corporate finance and divisional roles with his last position as Vice President, Finance and Pharmaceuticals CFO. Keith holds a Bachelor of Science degree in accounting from Manhattan College and is a Certified Public Accountant.

Gary Branch, VP, Sales

Gary Branch is LEO Pharma Inc.’s Vice President of Sales. Gary has more than 25 years of commercial experience in the pharmaceutical industry. Most recently, Gary served as the Vice President of Sales at Lexicon Pharmaceuticals, a start-up biopharma company, where he built the sales and sales support organization in preparation for the company’s first commercial launch. Prior to joining Lexicon, Gary spent many years at both Novartis and GlaxoSmithKline, where he held commercial positions of increasing responsibility in marketing, sales and managed care. Gary has deep breadth and depth in oncology and general medicines. He has worked in multiple countries and at the global level. Gary received his MBA from the University of Michigan Business School and his Bachelor of Science degree in engineering from the United States Military Academy at West Point.

Tiffany L. Christian, Head of U.S. Legal and Compliance

Tiffany L. Christian, Esq., is LEO Pharma Inc.’s Head of U.S. Legal and Compliance. Tiffany has over 15 years of experience in the pharmaceutical industry, supporting clients both as external and in-house counsel. Prior to joining LEO Pharma, Tiffany was Corporate Counsel at Warner Chilcott, where she provided general counsel and advice, with a focus on the advertising and promotion of pharmaceutical products. Prior to Warner Chilcott, Tiffany was a commercial litigation associate at DLA Piper, where she concentrated on product liability litigation and represented some of the largest pharmaceutical companies in the industry. Before DLA Piper, she was a litigation associate at Sills Cummis & Gross P.C. Tiffany holds a Juris Doctor from Georgetown University Law Center and a Bachelor of Arts degree from Cornell University.

Adriana Guana, VP, Medical Strategy & Scientific Affairs 

Adriana Guana, M.D., is Vice President of Medical Strategy & Scientific Affairs, and has a lead role in defining and driving the Medical and Scientific Affairs strategies in the U.S., as well as managing  Pharmacovigilance, Medical Information, Scientific Affairs and Field Medical. Adriana is a dermatologist, with more than 14 years of experience including phase III and phase IV clinical trials, pharmacovigilance and Medical Affairs-related activities, in the U.S. and globally. Adriana’s experience includes at Novartis, where she most recently served as Worldwide Lead Medical Affairs Director, Immunology and Dermatology. Prior to Novartis, Adriana held several roles of increasing responsibility at Sanofi. Adriana earned her M.D. degree from Pontificia Universidad Javeriana and completed her dermatology specialization at the Universidad Militar Nueva Granada, both in Colombia, with practice rotations at Baylor College of Medicine, the University of Texas and the University of Pittsburgh Medical School.


Mads Richard Hansen, Senior Director, Commercial Strategy and Operations
 
Mads Richard Hansen is LEO Pharma Inc.'s Senior Director of Commercial Strategy and Operations, which includes business development, forecasting, project and alliance management (authorized generics), commercial development and decision sciences. Mads has more than 17 years of strategy and operational experience with various industry and functions. He has spent nearly 10 years at LEO Pharma in roles of increasing responsibility, and most recently was Senior Director, Business Operations and Alliance Management, LEO Pharma Inc. His background includes experience as a senior consultant at Deloitte Business Consulting and project manager at Scandinavian Airline Systems. Mads earned a graduate degree in business administration, supply chain management, from the Copenhagen Business School in Denmark, and completed the academy profession program in economics and resource management from the Lyngby Business School, also in Copenhagen. 
 

Brian Mulnix, VP, Marketing

Brian Mulnix is LEO Pharma Inc.’s Vice President of Marketing. Prior to joining LEO Pharma, Brian was Head of Strategy and Business Development at Sun Pharmaceutical Industries where he negotiated pharmaceutical in-licensing and commercialization partnerships for U.S. and global markets. Previous to Sun, Brian was Vice President U.S. Marketing at Galderma. Brian was also the Xeljanz Commercial Team Leader, Enbrel Global Asset Leader and Enbrel U.S. Marketing Team Lead positions at Pfizer. Prior to Pfizer, Brian held global and regional roles at Endo Pharmaceuticals and Merck. Brian received his MBA from the University of Michigan Ross School of Business and his Bachelor of Science degree in applied economics from the University of Minnesota.

John Tomasello, VP and Head, Human Resources and Communications

John Tomasello is LEO Pharma Inc’s Vice President and Head of Human Resources and Communications. John is an HR executive with more than 20 years of multinational human resources experience, including more than 15 years within the healthcare industry. Prior to joining LEO Pharma, John was Vice President, Human Resources, at Mallinckrodt Pharmaceuticals where he was responsible for the company’s international, multibillion dollar specialty biopharmaceuticals portfolio (rare disease and hospital). Prior to Mallinckrodt, John held global, and U.S. HR leadership roles at Baxter International, The Valspar Corporation and Novartis. John holds a Master of Science degree in human resources and a Bachelor of Science degree in marketing from Rutgers University.

Domenic Verroca, VP, Patient Market Access and Public Affairs 

Domenic Verroca, Ph.D., is LEO Pharma Inc.’s Vice President of Market Access and Public Affairs. Domenic joined LEO Pharma after serving as Vice President of Market Access at Galderma. Prior to Galderma, Domenic worked at Sanofi for over 11 years in positions of increasing responsibility. His last position at Sanofi was as Vice President of U.S. Market Access, which he held for more than six years. Prior to Galderma, he worked for Pharmacia and Johnson & Johnson Health Care Systems Inc. Domenic holds a Bachelor of Arts degree in economics and geography from Coventry University in England, a Master of Arts degree in international affairs from Drew University and a Ph.D. in management from the University of Pittsburgh.

Global Leaders Based in U.S. 
 

Christian Antoni, SVP, Global Development

Christian Antoni, M.D., Ph.D., is Senior Vice President of Global Development at LEO Pharma. He is responsible for the development of the LEO Pharma pipeline and the strategic positioning of LEO Pharma in the field of medical dermatology. His organization consists of the full aspect of drug development including CMC and regulatory. Most recently, Christian built the immunology and inflammation franchise at Sanofi. Prior to that at Novartis, he was VP and Global Program Head responsible for bridging the link between the translational organization in the Novartis Institute of Biological Research and the development franchise for the autoimmune portfolio, and in 2012, he became the Global Program Head for the first anti-IL17 monoclonal antibody and created a development program in multiple indications. His experience also includes as Group Director, Clinical Immunology, for Schering Plough. Christian is a qualified M.D./Ph.D. and completed his medical training at Friedrich Alexander University in Germany, with residency training in internal medicine and rheumatology.
 

John Bujnoski, VP, Global Marketing Eczema

John Bujnoski is LEO Pharma’s Vice President of Global Marketing for the eczema portfolio. John has more than 25 years of global commercial experience and has led product teams that drive business results in the U.S. and globally. His experience includes senior level assignments in global organizations including Sandoz, Pfizer, Wyeth Pharmaceuticals and Merck. In addition to extensive U.S. experience, he has lived and worked in Italy and Germany. John holds an MBA from Florida State University and a Bachelor of Science degree in finance from the University of Florida.


Christine Garrett, VP, Global Head. Project Management

Christine Garrett, Ph.D., PMP, is Vice President and Global Head of Project Management at LEO Pharma. In this role, she leads the leaders and managers of global program teams in developing asset strategies, development and early lifecycle management plans. Chris has nearly two decades of experience in program leadership. Prior to LEO Pharma, Chris was Global Project Leader in research and early development at Celgene, leading development projects in immunology and inflammation, and hematology and oncology. Her experience includes nearly 17 years at Novartis in roles of increasing responsibility spanning pre-clinical to end-of-lifecycle programs, including as Global Program Head within cardio-metabolic and immunology and dermatology franchises, developing and executing program strategy and supporting portfolio expansion via in-licensing and partnerships. Prior to Novartis, she spent almost three years as a project leader and process chemist at Rohm & Haas, a specialty chemicals company. Chris earned her undergraduate degree in chemistry from the Rochester Institute of Technology and a Ph.D. in organic chemistry from MIT. She holds a Master’s Certificate in applied project management from Villanova University and Post-Graduate Certificate in pharmaceutical business development and licensing from the University of Manchester.

Beth-Anne Lang, VP, Global Regulatory Affairs

Beth-Anne Lang is Vice President of Global Regulatory Affairs at LEO Pharma. Beth joined LEO from Takeda where she spent the past 17 years in roles of increasing responsibility, and most recently was Vice President, Global Regulatory Affairs, for marketed products – spanning more than 400 products in 100 countries. She also previously worked at Abbott (AbbVie). She possesses a broad regulatory background in early and late-stage development across several therapeutic areas, including biologics. Beth has created numerous global regulatory strategies; built and developed large global teams; and has a strong command of U.S. and international regulatory environments. Beth earned her MBA from Marquette University and holds a Bachelor of Science in Microbiology from the University of Illinois.

Judit H. Nyirady, VP, Global Medical Affairs 

Judit H. Nyirady, M.D., is Vice President, Global Medical Affairs, and was most recently LEO Pharma Inc’s Vice President of Medical Strategy & Scientific Affairs. Judit has more than 20 years of pharmaceutical experience. Prior to joining LEO Pharma, Judit was the interim Medical Unit Head of Dermatology and Immunology at Novartis Pharmaceuticals Corporation. Additionally, she served as the Executive Director of U.S. Clinical Development and Medical Affairs and was the former Global Brand Medical Director of Dermatology. Prior to joining Novartis, Judit worked at Ortho Dermatological Johnson & Johnson Consumer Products Worldwide in Medical Affairs, Dermatology. She is a dermatologist, holds a MBA from Cornell University, Johnson Graduate School of Management, and obtained her medical diploma in Hungary from Albert Szent-Györgyi Medical University. Judit also serves as an Adjunct Assistant Professor in Dermatology at Rutgers University in Newark, N.J.

Visit our global company page for overview of:

LEO Pharma A/S Global Leadership Team and Board of Directors